Key result
The Sentinel Cerebral Protection System significantly reduced periprocedural strokes by 63% and 70% in the SENTINEL IDE Study and a recent all-comers trial, respectively.
Why the study?
Does the Sentinel Cerebral Protection System reduce periprocedural strokes in patients undergoing transcatheter aortic valve replacement and other endovascular procedures?
Does the Sentinel Cerebral Protection System reduce periprocedural strokes in patients undergoing transcatheter aortic valve replacement and other endovascular procedures?
Effect estimate: 63% and 70% reduction
The Sentinel Cerebral Protection System appears to significantly reduce the risk of periprocedural stroke during TAVR based on reviewed evidence.
May support Sentinel use in TAVR; leaves open confirmation in large randomized trials before routine adoption.
Stroke is a well-documented potential risk of structural cardiac interventions. As a result of the far-reaching burden of stroke on patients, caregivers and the healthcare system, new medical interventions and therapies are being developed to help mitigate this risk. One such intervention is the recently FDA-cleared Sentinel™ Cerebral Protection System (Sentinel; Claret Medical, Santa Rosa, CA, USA) designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures. In the SENTINEL IDE Study, and in a more recent all-comers trial, Sentinel significantly reduced periprocedural strokes by 63 and 70 % respectively. In this paper, we review the growing body of evidence supporting the use of Sentinel in transcatheter aortic valve replacement and other endovascular procedures.
No takes yet. Share an insight, caveat, or question.
Ulrich Schäfer (2017) conducted a review in Structural cardiac interventions / transcatheter aortic valve replacement. Sentinel Cerebral Protection System was evaluated on Periprocedural strokes (63% and 70% reduction). The Sentinel Cerebral Protection System significantly reduced periprocedural strokes by 63% and 70% in the SENTINEL IDE Study and a recent all-comers trial, respectively.